StockNow
Calendar
Log in
Other

Genmab (GMAB/GMAB DC) announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab

ORIGINAL · NewsquawkGenmab (GMAB/GMAB DC) announced positive topline results from the global Phase 3 LiGeR-HN1 trial evaluating petosemtamab
StockNow breaking-news AI analysis

Genmab announced positive topline results from the Phase 3 LiGeR-HN1 trial of petosemtamab, but the supplied record contains no supporting results or details.

1 stocks
GMABGenmab A/S ADS$57.08Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Ukrainian President Zelensky says negotiations between Ukraine, Russia and the US could take place as early as November 10th

Politics

Reports of a Yemeni attack targeting Saudi forces in Aden, Sabereen reports

U.S. Markets

Phillips 66 (PSX) Q3 2026 (USD): Adj. EPS 14.08 (exp. 11.73)

PSX